Articles with public access mandates - eslam 3bdelmonemLearn more
Not available anywhere: 28
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
M Eslam, J George
Nature reviews Gastroenterology & hepatology 17 (1), 40-52, 2020
Mandates: National Health and Medical Research Council, Australia
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach
T Tsutsumi, M Eslam, T Kawaguchi, S Yamamura, A Kawaguchi, ...
Hepatology Research 51 (11), 1115-1128, 2021
Mandates: National Health and Medical Research Council, Australia
Genetic and epigenetic mechanisms of NASH
M Eslam, J George
Hepatology international 10, 394-406, 2016
Mandates: National Health and Medical Research Council, Australia
The epigenetic drug discovery landscape for metabolic-associated fatty liver disease
A Bayoumi, H Grønbæk, J George, M Eslam
Trends in Genetics 36 (6), 429-441, 2020
Mandates: National Health and Medical Research Council, Australia
Genetic insights for drug development in NAFLD
M Eslam, J George
Trends in pharmacological sciences 40 (7), 506-516, 2019
Mandates: National Health and Medical Research Council, Australia
An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells
G Zhou, SDW Bae, R Nguyen, X Huo, S Han, Z Zhang, L Hebbard, ...
Cancer Letters 501, 124-132, 2021
Mandates: National Health and Medical Research Council, Australia
The role of IFN in the development of NAFLD and NASH
M Møhlenberg, E Terczynska-Dyla, KL Thomsen, J George, M Eslam, ...
Cytokine 124, 154519, 2019
Mandates: National Health and Medical Research Council, Australia, Danish Council for …
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?
MM Ramírez-Mejía, C Jiménez-Gutiérrez, M Eslam, J George, ...
Hepatology International 18 (1), 168-178, 2024
Mandates: National Health and Medical Research Council, Australia
A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients
M Eslam, GLH Wong, AM Hashem, HLY Chan, MJ Nielsen, DJ Leeming, ...
Official journal of the American College of Gastroenterology| ACG 116 (5 …, 2021
Mandates: National Health and Medical Research Council, Australia, Research Grants …
Genome-wide association studies and hepatitis C: harvesting the benefits of the genomic revolution
M Eslam, J George
Seminars in liver disease 35 (04), 402-420, 2015
Mandates: National Health and Medical Research Council, Australia
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis
S Fukunaga, D Nakano, T Tsutsumi, T Kawaguchi, M Eslam, S Yoshinaga, ...
Hepatology Research 52 (8), 699-711, 2022
Mandates: National Health and Medical Research Council, Australia
ABIDE: an accurate predictive model of liver decompensation in patients with nonalcoholic fatty liver‐related cirrhosis
L Calzadilla‐Bertot, E Vilar‐Gomez, VWS Wong, M Romero‐Gomez, ...
Hepatology 73 (6), 2238-2250, 2021
Mandates: National Health and Medical Research Council, Australia, Government of Spain
Targeting IFN-λ: therapeutic implications
M Eslam, J George
Expert Opinion on Therapeutic Targets 20 (12), 1425-1432, 2016
Mandates: National Health and Medical Research Council, Australia
MAFLD predicts cardiovascular disease risk better than MASLD
Z Pan, G Shiha, G Esmat, N Méndez‐Sánchez, M Eslam
Liver International, 2024
Mandates: National Health and Medical Research Council, Australia
Interferon lambda and liver fibrosis
M Eslam, G Ahlenstiel, J George
Journal of Interferon & Cytokine Research 39 (10), 627-635, 2019
Mandates: National Health and Medical Research Council, Australia
Reply to: Correspondence on “A new definition for metabolic associated fatty liver disease: an international expert consensus statement”: MAFLD: Moving from a concept to practice
M Eslam, J George
Journal of Hepatology 73 (5), 1268-1269, 2020
Mandates: National Health and Medical Research Council, Australia
An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities
Z Pan, JG Fan, M Eslam
Current Opinion in Pharmacology 60, 170-176, 2021
Mandates: National Health and Medical Research Council, Australia, National Natural …
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
H Zhang, G Targher, CD Byrne, SU Kim, VWS Wong, L Valenti, ...
Hepatology International, 1-24, 2024
Mandates: National Institute of Health and Medical Research, France, Government of …
Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation
M Alarabi, Z Pan, M Romero-Gómez, J George, M Eslam
Hepatology International, 1-11, 2024
Mandates: National Health and Medical Research Council, Australia
Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease
Z Pan, R El Sharkway, A Bayoumi, M Metwally, BS Gloss, R Brink, DB Lu, ...
Science Translational Medicine 16 (741), eadj0133, 2024
Mandates: National Health and Medical Research Council, Australia
Publication and funding information is determined automatically by a computer program